Comparative Pharmacology
Head-to-head clinical analysis: FERAHEME versus FERNDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERAHEME versus FERNDEX.
FERAHEME vs FERNDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
Ferndex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
Adults: 100 mg orally three times daily.
None Documented
None Documented
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged to 24-30 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <10%.
Category C
Category C
Iron Supplement
Iron Supplement